Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00692900 · ClinicalTrials.gov registry record · Phase 1
Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00692900 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 25 participants.
The verdict
NCT00692900, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safest and maximum tolerated dosing regimens for intraperitoneal oxaliplatin with intravenous docetaxel and intravenous oxaliplatin with intraperitoneal docetaxel for recurrent ovarian, primary peritoneal, or fallopian tube cancer.
Interventions
- DRUG intravenous docetaxel with intraperitoneal oxaliplatin
- DRUG intravenous oxaliplatin with intraperitoneal docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2008-12 |
| Est. Completion | 2013-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00692900
The ClinicalTrials.gov registry entry for NCT00692900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which intravenous docetaxel with intraperitoneal oxaliplatin is the first listed.
NCT00692900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00692900 about?
NCT00692900 is a clinical study titled "Safety Study Involving Oxaliplatin With Docetaxel for Recurrent Ovarian,Primary Peritoneal, and Fallopian Tube Cancer". The purpose of this study is to determine the safest and maximum tolerated dosing regimens for intraperitoneal oxaliplatin with intravenous docetaxel and intravenous oxaliplatin with intraperitoneal docetaxel for recurrent ovarian, primary peritoneal, or fallopian tube cancer.
What is the current status of trial NCT00692900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2008-12. Estimated completion is 2013-10.
What interventions are being tested in trial NCT00692900?
The interventions under investigation include: intravenous docetaxel with intraperitoneal oxaliplatin (DRUG), intravenous oxaliplatin with intraperitoneal docetaxel (DRUG).
Who is sponsoring clinical trial NCT00692900?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.